Last reviewed · How we verify

Pneumonia due to Streptococcus — Treatment Landscape & Competitive Intelligence

Pneumonia due to Streptococcus (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Pneumonia due to Streptococcus, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Xenleta LEFAMULIN Hong Kong Pleuromutilin Antibacterial 2019-01-01
Tygacil TIGECYCLINE Fresenius Kabi Tetracycline-class Antibacterial [EPC] 30S ribosomal subunit 2005-01-01
Zymar GATIFLOXACIN Allergan DNA gyrase, DNA gyrase, DNA gyrase subunit A 2003-01-01
Zyvox linezolid Pfizer Oxazolidinone Antibacterial [EPC] Amine oxidase [flavin-containing] A 2000-01-01
Avelox moxifloxacin Bayer AG Fluoroquinolone antibiotic (fourth-generation) DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A 1999-12-10
Tomefloxacin GREPAFLOXACIN Otsuka grepafloxacin Potassium voltage-gated channel subfamily H member 2 1997-01-01
ALATROFLOXACIN ALATROFLOXACIN Pfizer alatrofloxacin 1997-01-01
Levaquin levofloxacin Generic (originally Daiichi Sankyo/J&J) Fluoroquinolone Antibacterial [EPC] CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2 1996-12-20
Maxipime CEFEPIME Baxter Cephalosporin Antibacterial 1996-01-01
Maxipime Cefepime Hydrochloride Baxter Cephalosporin Bacterial cell wall peptidoglycan 1996-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. · 13 drugs in Pneumonia due to Streptococcus
  2. Pfizer · 6 drugs in Pneumonia due to Streptococcus
  3. GSK · 4 drugs in Pneumonia due to Streptococcus
  4. Bristol-Myers Squibb · 3 drugs in Pneumonia due to Streptococcus
  5. Bayer AG · 2 drugs in Pneumonia due to Streptococcus
  6. Baxter · 2 drugs in Pneumonia due to Streptococcus
  7. Pai Holdings Pharm · 2 drugs in Pneumonia due to Streptococcus
  8. Centre Hospitalier Universitaire Vaudois · 1 drug in Pneumonia due to Streptococcus
  9. Generic (originally Daiichi Sankyo/J&J) · 1 drug in Pneumonia due to Streptococcus
  10. Assistance Publique - Hôpitaux de Paris · 1 drug in Pneumonia due to Streptococcus
  11. Generic (originally Beecham/GSK) · 1 drug in Pneumonia due to Streptococcus
  12. Fresenius Kabi · 1 drug in Pneumonia due to Streptococcus

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pneumonia due to Streptococcus:

Cite this brief

Drug Landscape (2026). Pneumonia due to Streptococcus — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pneumonia-due-to-streptococcus. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing